The prevalence of diabetes is increasing worldwide, bringing personal and economic burdens. Impaired glucose tolerance (IGT) generally precedes type 2 diabetes and strategies which target IGT and delay or prevent the onset of type 2 diabetes are being explored. IGT and type 2 diabetes are characterised by insulin resistance. Lifestyle and pharmacological approaches which ameliorate insulin resistance are being investigated as methods of diabetes prevention.
International Diabetes Federation. Diabetes Atlas2000.
2.
Amos AF, McCarty DJ, Zimmet P.The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med1997 ;14(suppl 5):S1-S85.
3.
Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care2001;24:1936-40.
4.
Mokdad AS, Ford EH, Bowman BA et al. Diabetes trends in the US: 1990-1998. Diabetes Care2000;23:1278-83.
5.
Paeratakul S. , Lovejoy JC, Ryan DH, Bray GAThe relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes Relat Metab Disord2002;26:1205-10.
6.
Swinburn BA, Metcalf PA, Ley SJLong-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care2001 ;24:619-24.
7.
Hu FB, Leitzmann MF, Stampfer MJ et al. Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med2001;161:1542-8.
8.
Burrows NR, Geiss LS, Engelgau MM, Acton KJPrevalence of diabetes among Native Americans and Alaska Natives, 1990-1997: an increasing burden. Diabetes Care2000;23:1278-83.
9.
Lorenzo C., Serrano-Rios M., Martinez-Larrad MT et al. Was the historic contribution of Spain to the Mexican gene pool partially responsible for the higher prevalence of type 2 diabetes in Mexican-origin populations? The Spanish Insulin Resistance Study Group, the San Antonio Heart Study, and the Mexico City Diabetes Study. Diabetes Care2001;24: 2059-64.
10.
Burden ACBlood pressure control and cardiovascular risk in patients of Indo-Asian and African-Caribbean descent. Int J Clin Pract1998;52: 388-94.
11.
Abate N., Chandalia M.Ethnicity and type 2 diabetes: focus on Asian Indians. J Diabetes Complications2001;15:320-7.
12.
Aschner P.Diabetes trends in Latin America. Diabetes Metab Res Rev2002;18(suppl 3):S27-S31.
13.
Skyler JS, Oddo C.Diabetes trends in the USA. Diabetes Metab Res Rev2002;18(suppl 3):S21-S26.
14.
Bagust A., Hopkinson PK, Maier W., Currie CJAn economic model of the long-term health care burden of type II diabetes . Diabetologia2001;44:2140-55.
15.
Bagust A., Hopkinson PK, Maslove L., Currie CJThe projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet Med2002;19(suppl 4):1-5.
16.
Gray A., Raikou M., McGuire A. et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ2000; 320:1373-8.
17.
Clarke P., Gray A., Adler A. et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51) . Diabetologia2001;44:298-304.
18.
UK Prospective Diabetes Study Group.Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
19.
DeFronzo RA , Bonnadonna RC, Ferrannini E.Pathogenesis of NIDDM. A balanced overview . Diabetes Care1992;15:318-68.
20.
DeFronzo RAInsulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis . Neth J Med1997;50:191-7.
21.
Köhler C., Henkel E., Temelkova-Kurktschiev T. et al. Incidence of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes in a German risk population: the RIAD study. Diabetologia2001; 44(suppl 1):A108.
22.
American Diabetes Association.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care1997;20:1183-97.
23.
Lim SC, Tai ES, Tan BY, Chew SK, Tan CECardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care2000;23:278-82.
24.
Temelkova-Kurktschiev T., Siegert G., Bergmann S. et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism2002 ;51:743-9.
25.
Hanefeld M., Köhler C., Henkel E.Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intimamedia thickness: the RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med2000;17:835-40.
26.
Saydah SH, Miret M., Sung J., Varas C., Gause D., Brancati FLPostchallenge hyperglycemia and mortality in a national sample of U.S. adults . Diabetes Care2001;24:1397-402.
27.
Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343-50.
28.
Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care1997;20:537-44.
29.
Wenying Y., Lixiang L., Jinwu Q., Guangwei L., Zhiqing Y., Xiaoren P.The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab2001;17:131-4.
30.
Diabetes Prevention ProgramResearch Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med2002;346:393-403.
31.
Chiasson J-L. , Josse RG, Gomis R., Hanefeld M., Karasik A., Laakso M.Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomised clinical trial: the STOP-NIDDM trial. Lancet2002;359:2072-7
